Literature DB >> 2866712

Pathogenesis and pharmacologic management of pseudo-obstruction of the bowel in pheochromocytoma.

J P Mullen, R C Cartwright, S E Tisherman, J R Misage, A P Shapiro.   

Abstract

Metastatic malignant pheochromocytoma can be a disease of long duration and though poorly responsive to both radiation therapy and chemotherapy, pharmacologic management of its myriad manifestations can be very effective. Hypertension is the most recognized feature of this disease, but gastrointestinal manifestations can, on rare occasions, be just as serious and life threatening. We present two patients with metastatic pheochromocytoma who developed pseudo-obstruction, and discuss the pathopharmacology and treatment of this syndrome.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2866712     DOI: 10.1097/00000441-198510000-00004

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  6 in total

Review 1.  Pheochromocytoma as an endocrine emergency.

Authors:  Frederieke M Brouwers; Jacques W M Lenders; Graeme Eisenhofer; Karel Pacak
Journal:  Rev Endocr Metab Disord       Date:  2003-05       Impact factor: 6.514

2.  Phaeochromocytoma presenting with pseudo-intestinal obstruction and lactic acidosis.

Authors:  Peng Chin Kek; Emily Tse Lin Ho; Lih Ming Loh
Journal:  Singapore Med J       Date:  2015-08       Impact factor: 1.858

Review 3.  A case of pheochromocytoma with severe paralytic ileus.

Authors:  M Noguchi; T Taniya; K Ueno; M Yagi; R Izumi; K Konishi; I Miyazaki
Journal:  Jpn J Surg       Date:  1990-07

Review 4.  Pheochromocytoma.

Authors:  William M Manger; Ray W Gifford
Journal:  J Clin Hypertens (Greenwich)       Date:  2002 Jan-Feb       Impact factor: 3.738

5.  Treatment-resistant hypertension in a post-transplant patient with cystic fibrosis: a rare case of phaeochromocytoma.

Authors:  David Joseph Tansey; Jim John Egan; Michelle Murray; Katie Padfield; John Conneely; Mensud Hatunic
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2021-06-01

Review 6.  Tumor-related dysmotility: gastrointestinal dysmotility syndromes associated with tumors.

Authors:  J K DiBaise; E M Quigley
Journal:  Dig Dis Sci       Date:  1998-07       Impact factor: 3.487

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.